179 related articles for article (PubMed ID: 28275291)
1. Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB.
Brindha S; Sundaramurthi JC; Velmurugan D; Vincent S; Gnanadoss JJ
Bioinformation; 2016; 12(8):359-367. PubMed ID: 28275291
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics approach to prioritize known drugs towards repurposing for tuberculosis.
Brindha S; Vincent S; Velmurugan D; Ananthakrishnan D; Sundaramurthi JC; Gnanadoss JJ
Med Hypotheses; 2017 Jun; 103():39-45. PubMed ID: 28571806
[TBL] [Abstract][Full Text] [Related]
3. Repurposing of FDA-approved drugs to target MurB and MurE enzymes in
Rani J; Silla Y; Borah K; Ramachandran S; Bajpai U
J Biomol Struct Dyn; 2020 Jun; 38(9):2521-2532. PubMed ID: 31244382
[TBL] [Abstract][Full Text] [Related]
4.
Jagadeb M; Rath SN; Sonawane A
J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
[TBL] [Abstract][Full Text] [Related]
5. Structure based virtual screening to identify inhibitors against MurE Enzyme of Mycobacterium tuberculosis using AutoDock Vina.
Singh S; Bajpai U; Lynn AM
Bioinformation; 2014; 10(11):697-702. PubMed ID: 25512687
[TBL] [Abstract][Full Text] [Related]
6. In Silico Drug Repurposing Studies for the Discovery of Novel Salicyl-AMP Ligase (MbtA)Inhibitors.
Rakshit G; Biswas A; Jayaprakash V
Pathogens; 2023 Dec; 12(12):. PubMed ID: 38133316
[TBL] [Abstract][Full Text] [Related]
7. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
Uddin R; Zahra NU; Azam SS
Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
10. In Silico Drug Repurposing Approach: Investigation of
Ngidi NTP; Machaba KE; Mhlongo NN
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163931
[No Abstract] [Full Text] [Related]
11. A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles.
Battah B; Chemi G; Butini S; Campiani G; Brogi S; Delogu G; Gemma S
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795400
[TBL] [Abstract][Full Text] [Related]
12. Multiscale Virtual Screening Optimization for Shotgun Drug Repurposing Using the CANDO Platform.
Hudson ML; Samudrala R
Molecules; 2021 Apr; 26(9):. PubMed ID: 33925237
[TBL] [Abstract][Full Text] [Related]
13.
Sarı S; Avci A; Koçak Aslan E
Turk J Pharm Sci; 2021 Dec; 18(6):730-737. PubMed ID: 34978402
[TBL] [Abstract][Full Text] [Related]
14. Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant Tuberculosis.
Sharma D; Dhuriya YK; Deo N; Bisht D
Front Microbiol; 2017; 8():2452. PubMed ID: 29321768
[TBL] [Abstract][Full Text] [Related]
15. DrugRep: an automatic virtual screening server for drug repurposing.
Gan JH; Liu JX; Liu Y; Chen SW; Dai WT; Xiao ZX; Cao Y
Acta Pharmacol Sin; 2023 Apr; 44(4):888-896. PubMed ID: 36216900
[TBL] [Abstract][Full Text] [Related]
16. Multifaceted role of drugs: a potential weapon to outsmart
Tanweer S; Jamal S; Mehra S; Saqib N; Ahmad F; Faizan ; Grover A; Grover S
J Biomol Struct Dyn; 2022 Nov; 40(18):8508-8517. PubMed ID: 33860725
[TBL] [Abstract][Full Text] [Related]
17. Unravelling the potential of Triflusal as an anti-TB repurposed drug by targeting replication protein DciA.
Ali W; Jamal S; Gangwar R; Ahmed F; Pahuja I; Sharma R; Prakash Dwivedi V; Agarwal M; Grover S
Microbes Infect; 2024; 26(3):105284. PubMed ID: 38145750
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive molecular docking and dynamic simulations for drug repurposing of clinical drugs against multiple cancer kinase targets.
Shaikh N; Linthoi RK; Swamy KV; Karthikeyan M; Vyas R
J Biomol Struct Dyn; 2023; 41(16):7735-7743. PubMed ID: 36134605
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis.
Swaminathan S; Sundaramurthi JC; Palaniappan AN; Narayanan S
Tuberculosis (Edinb); 2016 Dec; 101():31-40. PubMed ID: 27865394
[TBL] [Abstract][Full Text] [Related]
20. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis.
Maitra A; Bates S; Kolvekar T; Devarajan PV; Guzman JD; Bhakta S
Int J Infect Dis; 2015 Mar; 32():50-5. PubMed ID: 25809756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
